London, UK (PRWEB) May 20, 2014
At present, the overall ovarian cancer therapeutics market is led by the use of generics, especially paclitaxel and carboplatin, which are used in combination to treat recurrent and first-line platinum-sensitive diseases. There exists a clear gap in the world ovarian cancer market for maintenance therapies to increase the initial high rates of remission as well as successfully stimulate long-term remission in potential patents. Moreover, there is a gap for more effective treatments of refractory or platinum-resistant patients. The actual developmental pipeline addresses the existing gaps in the ovarian cancer therapeutics market.
The robust growth in the worldwide ovarian cancer therapeutics market is predicted to be spurred by novel drug approvals (but primarily inflation), high unmet clinical needs and also the rising prevalence of pancreatic cancer. In the years ahead, the global ovarian cancer therapeutics market is anticipated to post a 3.4% CAGR, and in 2020, the market value will likely reach USD 1.9 billion. There is a high number of promising drug candidates in the present developmental pipeline (especially in the preclinical phase) including, among others, Farletuzumab, Niraparib, Vargatef, Karenitecin, Abagovomab and Telcyta.
New comprehensive research report “Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies” elaborated by GBI Research is now available at MarketPublishers.com.
Title: Ovarian Cancer Therapeutics in Major Developed Markets to 2020 - Late-Stage Pipeline Focuses on Improved Progression Free-Surival and Targeted Therapies
Published: May, 2014
Price: US$ 3,500.00
The cutting-edge study presents an insightful guide to the ovarian cancer therapeutics market in the major developed countries (namely Italy, Japan, the US, Spain, Canada, France, Germany and the UK) as well as scrutinizes the treatment usage patterns. It provides an all-round overview of the available drug types; offers a comprehensive analysis of the ovarian cancer pipeline with a close look at late-stage pipeline drugs having huge future potential; includes a disease profile for ovarian cancer, encompassing details on the decease’s pathophysiology, symptoms and diagnosis, risk factors, treatment algorithm, etc. The topical report encloses an extensive examination of various drug combinations used for ovarian cancer treatment and includes vital details on their efficacy and safety; and also contains an insightful summary of pipeline clinical drug trials by molecule type, phase, trial size and duration. The research study investigates the key market growth barriers and drivers, touches upon the co-development and licensing deals issues, thoroughly discusses the most prominent industry concerns and, furthermore, gives access to multi-scenario forecast data for the major developed ovarian cancer therapeutics markets through 2020.
Reasons to Buy:
- The report will enhance understanding of the world’s major developed markets for ovarian cancer therapeutics, thus, assist business development and also enable marketing executives to strategize your product launches.
- Find out about the safety and efficacy of the currently available monotherapies and also drug combinations used for ovarian cancer treatment.
- Gain a comprehensive understanding of the major molecular targets and signaling pathways presently under investigation in ovarian cancer drug development.
- Get a clear idea of the vast scope of the ovarian cancer pipeline and point out the most promising candidates in the pipeline.
- Become abreast of the top trends in the clinical trials and also use the analysis of the clinical trial failure rate to evaluate the risk profiles of the actual or/and future developmental programs for ovarian cancer therapeutics.
- Assess the most lucrative opportunities emerging in the major developed ovarian cancer therapeutics markets and learn how to better exploit them.
More new market research reports by the publisher can be found at GBI Research page.